Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Bausch + Lomb Corporation ( (BLCO) ) is now available.
At its Annual Meeting of Shareholders held on May 20, 2026, Bausch + Lomb Corporation’s investors elected a full slate of directors, including Eduardo Alfonso, Nathalie Bernier and Brenton L. Saunders, to serve on the board until the close of the 2027 annual meeting or until successors are chosen. The voting results, showing strong support for all nominees with limited opposition and broker non-votes, indicate continuity in the company’s governance and strategic oversight for the coming year.
Shareholders also approved, on a non-binding advisory basis, the compensation packages for the company’s named executive officers as described in the proxy materials. This endorsement of executive pay suggests investors are broadly aligned with Bausch + Lomb’s compensation practices and leadership direction, reinforcing management’s position and potentially providing stability for ongoing operational and strategic initiatives.
The most recent analyst rating on (BLCO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
The score is anchored by improving fundamentals but still-limited quality of earnings: revenue and operating profitability are trending better and leverage has improved, yet net losses and thin free-cash-flow conversion remain key constraints. The latest earnings call was a clear positive with raised guidance and strong margin expansion, but technicals are weak (below key moving averages with negative MACD) and valuation lacks support given losses and no dividend.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation operates in the healthcare sector, focusing on eye health products and services. The company’s portfolio typically includes contact lenses, lens care products, ocular pharmaceuticals and surgical devices aimed at vision care and ophthalmic treatments worldwide.
Average Trading Volume: 446,327
Technical Sentiment Signal: Buy
Current Market Cap: $5.74B
For an in-depth examination of BLCO stock, go to TipRanks’ Overview page.